PEGylated solid lipid nanoparticles functionalized by aptamer for targeted delivery of docetaxel in mice bearing C26 tumor

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103.
   PubMed Web of Science ®Google Scholar
• Coppedè F, Lopomo A, Spisni R, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol. 2014;20(4):943–956.
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Taghdisi SM, Ramezani P, et al. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo. Int J Pharm. 2017;519(1–2):352–364.
   PubMed Web of Science ®Google Scholar
• Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(3):133–140.
   PubMedGoogle Scholar
• Wang L, Liu Z, Liu D, et al. Docetaxel-loaded-lipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413(1–2):194–201.
   PubMed Web of Science ®Google Scholar
• Chen DB, Yang TZ, Lu WL, et al. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull. 2001;49(11):1444–1447.
   PubMed Web of Science ®Google Scholar
• Mosallaei N, Jaafari MR, Hanafi-Bojd MY, et al. Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations. J Pharm Sci. 2013;102(6):1994–2004.
   PubMed Web of Science ®Google Scholar
• Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec. 2001;1(3):195–211.
   PubMedGoogle Scholar
• Chen DB, Yang TZ, Lu WL, et al. [In vitro and in vivo study of two kinds of long-circulating solid lipid nanoparticles containing paclitaxel]. Yao Xue Xue Bao. 2002;37(1):54–58.
   PubMedGoogle Scholar
• Fan R, Tong A, Li X, et al. Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Int J Nanomedicine. 2015;10:7291–7305.
   PubMed Web of Science ®Google Scholar
• Andisheh F, Oroojalian F, Shakour N, et al. Docetaxel encapsulation in nanoscale assembly micelles of folate-PEG-docetaxel conjugates for targeted fighting against metastatic breast cancer in vitro and in vivo. Int J Pharm. 2021;605:120822.
   PubMedGoogle Scholar
• Fernandes MA, Eloy JO, Luiz MT, et al. Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells. Colloids Surf, A Physicochem Eng Asp. 2021;611(125806).
   Google Scholar
• Yu Z, Li X, Duan J, et al. Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel. Int J Nanomed. 2020;15:6737–6748.
   PubMed Web of Science ®Google Scholar
• Haghshenas V, Sariri R, Naderi Sohi A, et al. Encapsulation of docetaxel into diblock polymeric polymersome as a nanodrug. ChemistrySelect. 2020;5(29):8924–8928.
   Google Scholar
• Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491–504.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–1272.
   PubMed Web of Science ®Google Scholar
• Gao K, Sun J, Liu K, et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm. 2008;34(11):1227–1237.
   PubMed Web of Science ®Google Scholar
• Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71(3):409–419.
   PubMed Web of Science ®Google Scholar
• Benhabbour SR, Luft JC, Kim D, et al. In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel heptameric ZEGFR domain. J Control Release. 2012;158(1):63–71.
   PubMedGoogle Scholar
• Naguib YW, Rodriguez BL, Li X, et al. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 2014;11(4):1239–1249.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615–1626.
   PubMed Web of Science ®Google Scholar
• Catuogno S, Esposito CL, de Franciscis V. Aptamer-mediated targeted delivery of therapeutics: an update. Pharmaceuticals. 2016;9(4):69.
   Google Scholar
• Moosavian SA, Sahebkar A. Aptamer-functionalized liposomes for targeted cancer therapy. Cancer Lett. 2019;448:144–154.
   PubMed Web of Science ®Google Scholar
• Zhou G, Wilson G, Hebbard L, et al. Aptamers: a promising chemical antibody for cancer therapy. Oncotarget. 2016;7(12):13446–13463.
   PubMedGoogle Scholar
• Alibolandi M, Abnous K, Ramezani M, et al. Synthesis of AS1411-aptamer-conjugated CdTe quantum dots with high fluorescence strength for probe labeling tumor cells. J Fluoresc. 2014;24(5):1519–1529.
   PubMedGoogle Scholar
• Reyes-Reyes EM, Teng Y, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617–8629.
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Abnous K, Akhtari J, et al. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(8):2054–2065.
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Abnous K, Badiee A, et al. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids Surf B Biointerfaces. 2016;139:228–236.
   PubMed Web of Science ®Google Scholar
• Anshida M, Shaji LK, Nair A K, et al. Characterization of nanomaterials: Morphological characterization of nanomaterials. Cambridge: Elsevier; 2018.
   Google Scholar
• Mahmoudi A, Jaafari MR, Ramezanian N, et al. BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers. Int J Pharm. 2019;564:77–89.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
   PubMed Web of Science ®Google Scholar
• Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):8010–8020.
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Yang Z, et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials. 2012;33(26):6264–6272.
   PubMedGoogle Scholar
• Barzegar Behrooz A, Nabavizadeh F, Adiban J, et al. Smart bomb AS1411 aptamer-functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer. Clin Exp Pharmacol Physiol. 2017;44(1):41–51.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu J, Li X, et al. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv. 2007;14(6):381–387.
   PubMed Web of Science ®Google Scholar
• Yan F, Zhang C, Zheng Y, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2010;6(1):170–178.
   PubMed Web of Science ®Google Scholar
• Rohit B, Pal K. A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs. CNANO. 2013;9(2):211–220.
   Google Scholar
• Esmaeili F, Dinarvand R, Ghahremani MH, et al. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles. Anticancer Drugs. 2010;21(1):43–52.
   PubMed Web of Science ®Google Scholar
• Zhao J, Kim JE, Reed E, et al. Molecular mechanism of antitumor activity of taxanes in lung cancer (review). Int J Oncol. 2005;27(1):247–256.
   PubMedGoogle Scholar
• Xu G, Yu X, Zhang J, et al. Robust aptamer-polydopamine-functionalized M-PLGA-TPGS nanoparticles for targeted delivery of docetaxel and enhanced cervical cancer therapy. Int J Nanomedicine. 2016;11:2953–2965.
   PubMed Web of Science ®Google Scholar
• Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011;79(2):276–284.
   PubMed Web of Science ®Google Scholar
• Ngoune R, Peters A, von Elverfeldt D, et al. Accumulating nanoparticles by EPR: a route of no return. J Control Release. 2016;238:58–70.
   PubMed Web of Science ®Google Scholar
• Yazdian-Robati R, Bayat P, Oroojalian F, et al. Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol. 2020;155:1420–1431.
   PubMed Web of Science ®Google Scholar